drugset
drugset / Trial / NCT00750698

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

NCT00750698 ↗

Phase 2 Terminated 8 enrolled Syndax Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the tumor responses to SNDX-275 (entinostat) in combination with continued erlotinib in participants with non-small Cell Lung Carcinoma (NSCLC) who are progressing on erlotinib.

Timeline

Start
2008-08
Primary completion
2010-05
Completion
2010-06

Outcome

Outcome not reported

Stopped (Enrollment): “Due to business reasons, enrollment on the study was halted and the study terminated. The decision to close enrollment was not due to any safety concern.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Entinostat Small molecule 10 mg Oral
Background Erlotinib Small molecule 150 mg Oral

Indications

non-small cell lung carcinoma